APAC IPOs & Placements, Aequitas Research

Hong Jie Seow

At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

APAC IPOs & Placements

Aequitas: Hangzhou Diagens Biotech IPO Trading - Priced At Mid-Range, Weak Insti Demand

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Hangzhou Diagens Biotechnology / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/hangzhou-diagens-biotechnology" target="_blank" data-smartkarma-citation="entities:45431:1" rel="noopener">Hangzhou Diagens Biotechnology (HDB HK)</a> is looking to raise US$114m in its Hong Kong IPO.</li>
<li>Hangzhou Diagens Biotechnology (HDB) is a medical device company focused on developing medical imaging products and services. </li>
<li>In this note, we talk about past performances and valuations.</li>
</ul>



Hangzhou Diagens Biotechnology (HDB HK) is looking to raise US$114m in its Hong Kong IPO.
Hangzhou Diagens Biotechnology (HDB) is a medical device company focused on developing medical imaging products and services. 
In this note, we talk about past performances and valuations.


Aequitas: Hangzhou Diagens Biotechnology IPO - Aggressive Pricing Leaves No Room For Error